Close Menu

NEW YORK – Advanced lung cancer patients with ALK rearrangements may soon have another ALK inhibitor to choose from as a front-line option according to interim Phase III study data presented at the European Society for Medical Oncology's Virtual Congress on Saturday.

Data from a planned interim analysis in the CROWN trial comparing Pfizer's third-generation ALK inhibitor lorlatinib (Lorbrena) against its first-generation drug crizotinib (Xalkori) showed that the newer agent shrunk tumors in 76 percent of patients compared to a 58 percent overall response rate with the older drug.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.